Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Over the past 20 years, substantial advances have been made in the treatment of patients with metastatic colorectal cancer (mCRC). In particular, there is now a wide range of options for the front-line treatment of mCRC. Sophisticated molecular technologies have been developed to identify novel prognostic and predictive biomarkers for CRC. DNA sequencing technology has made remarkable advances in recent years, primarily as a result of the development of next-generation sequencing and whole exome sequencing, which are powerful new tools for the discovery of predictive molecular biomarkers to facilitate the delivery of personalized medicine. In addition to tumor tissue, recent efforts have focused on analyzing circulating tumor DNA in peripheral blood. Herein, we review the evolution of standard chemotherapy and targeted therapy strategies for the treatment of mCRC in the front-line setting, the molecular technologies that are presently being used to facilitate our ability to practice individualized medicine, and the practical aspects of applying molecular biomarkers to everyday clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, an improved surgical resection rate was found with triplet therapy [143].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [143]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Research works printed but not linked: 8
- Weinberg BA, 2016, Clin Adv Hematol Oncol, 14, 116
- Venook A, 2006, J Clin Oncol
- 10.1186/s13059-014-0454-7 · doi:10.1186/s13059-014-0454-7 · Paper page
- Raghav KPS, 2016, J Clin Oncol, 34
- Sartore-Bianchi A, 2015, J Natl Cancer Inst, 108, djv306
- Seligmann JF, Ann Oncol
- Sehdev A, 2016, Discov Med, 21, 341
- Corcoran R, 2016, Ann Onco, 27, vi1
Cited by
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota
Sougiannis, A. T., VanderVeen, B. N., Enos, R. T., Velázquez, K. T., Bader, J. E., Carson, M. S., Chatzistamou, I., Walla, M. D., Pena, M. M., Kubinak, J. L., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.02.020 · Cited by 152
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 132
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 122
Angiogenin promotes colorectal cancer metastasis via tiRNA production
Li, S., Shi, X., Chen, M., Xu, N., Sun, D., Bai, R., Chen, H., Ding, K., Sheng, J., & Xu, Z. (2019) · International Journal of Cancer · doi:10.1002/ijc.32245 · Cited by 112
Shen, X., Hu, X., Mao, J., Wu, Y., Liu, H., Shen, J., Yu, J., & Chen, W. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2254-1 · Cited by 95
Garcia-Carbonero, N., Martínez‐Useros, J., Li, W., Orta, A., Pérez, N. T. I., Caramés, C., Hernández, T., Moreno, I., Serrano, G., & García‐Foncillas, J. (2020) · Cells · doi:10.3390/cells9010219 · Cited by 86
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Furthermore, an improved surgical resection rate was found with triplet therapy [143].”
BackgroundTargeting Myc-driven stress addiction in colorectal cancer
Saeed, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100963 · Cited by 61
Yang, D., Zhang, X., Zhang, W., & Thamaraiselvan, R. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s149307 · Cited by 59
Taguchi, N., Oda, S., Yokota, Y., Yamamura, S., Imuta, M., Tsuchigame, T., Nagayama, Y., Kidoh, M., Nakaura, T., Shiraishi, S., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.06.028 · Cited by 53
Wang, G., He, Y., Sun, Y., Wang, W., Qian, X., Yu, X., & Pan, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02213-9 · Cited by 47
Yan, L., Shi, J. H., & Zhu, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01163-1 · Cited by 45
“In addition, The production of reactive oxygen species (ROS) is a byproduct of the energy generation and maintenance of cancer cells’ rapid proliferation, both of which are facilitated by metabolic intermediates, which are more abundant in cancer cells.”
BackgroundTong, F., Ying, Y., Pan, H., Wei, Z., Li, H., & Zhan, X. (2018) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2018.2376 · Cited by 42
Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility
Silva, M. D., Tse, B. C. Y., Diakos, C. I., Clarke, S. J., & Molloy, M. P. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03641-5 · Cited by 35
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Hyung, J., Cho, E. J., Kim, J., Kim, J. H., Kim, J. E., Hong, Y. S., Kim, T. W., Sung, C. O., & Kim, S. Y. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1133 · Cited by 30
Imbastari, F., Dahlmann, M., Sporbert, A., Mattioli, C. C., Mari, T., Scholz, F., Timm, L., Twamley, S., Migotti, R., Walther, W., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03734-1 · Cited by 30
Qiu, M., Bai, Y., Wang, J., Gu, K., Yang, M., He, Y., Cheng, Y., Jin, Y., Liu, B., Wang, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02063-0 · Cited by 26
Brain metastasis in pancreatic cancer: Two case reports
Sasaki, T., Sato, T., Nakai, Y., Sasahira, N., Isayama, H., & Koike, K. (2019) · Medicine · doi:10.1097/md.0000000000014227 · Cited by 24
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Self-citationBiliary tract cancer prognostic and predictive genomics
Mondaca, S., Nervi, B., Pinto, M. P., & Abou‐Alfa, G. K. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.06 · Cited by 23
Chowdhury, S., Xiu, J., Ribeiro, J. R., Nicolaides, T. P., Zhang, J., Korn, W. M., Poorman, K. A., Lenz, H., Marshall, J. L., Oberley, M. J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02826-0 · Cited by 21
Ades, S., Pulluri, B., Holmes, C. E., Lal, I., Kumar, S., & Littenberg, B. (2022) · Cancer Medicine · doi:10.1002/cam4.4581 · Cited by 18
The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer
Reed, M., Patrick, C., Croft, B., Walde, N., & Voutsadakis, I. A. (2019) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0923-0 · Cited by 8
Wu, J., Sheng, J., Qin, H., Cui, M., Yang, Y., & Zhang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628636 · Cited by 7
Jafarlou, V., & Jafarlou, M. (2025) · Asian Pacific Journal of Cancer Care · doi:10.31557/apjcc.2025.10.3.861-869 · Cited by 6
Hawi, G., Kim, P., & Lee, P. P. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112231 · Cited by 5
Marschner, N. W., Seufferlein, T., Potthoff, K., Zahn, M., Uhlig, J., Dörfel, S., Karcher, A., Sauer, A., Maintz, C., Fruehauf, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100040 · Cited by 5
Österlund, E., & Glimelius, B. L. G. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2126327 · Cited by 5
“International collaborative groups ’ or consensus documents state, e.g., that ‘ median survival of 24 – 30 months can be expected for patients diagnosed with mCRC, as opposed to about 6 months some decades ago ’ [6] or that ‘ median OS is now in the 30-month range ’ [11].”
Tian, T., Han, H., Huang, J., Ma, J., & Ran, R. (2025) · Biomedicines · doi:10.3390/biomedicines13051115 · Cited by 4
“Furthermore, despite promising results from early-phase trials of immune checkpoint inhibitors in MSI-H and mismatch repair-deficient tumors, additional studies are required to confirm their safety and efficacy [3–6].”
mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
Leibowitz, B. J., Zhao, G., Xia, W., Wang, Y., Ruan, H., Zhang, L., & Yu, J. (2023) · Oncogene · doi:10.1038/s41388-023-02706-6 · Cited by 4
Kakati, R. T., Faraj, W. G., Qaraqe, T. M., Chaer, F. E., Hussain, H. K., Shamseddine, A. I., & Khalife, M. J. (2022) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjac142 · Cited by 3
Clinicoepidemiological Study and Survival Analysis of Right versus Left Sided Colon Cancer Patients
Regeai, R. M., Faraj, A. L., & Tawfik, A. S. (2017) · The Egyptian Journal of Hospital Medicine · doi:10.12816/0040139 · Cited by 2
“Figure (7): Kaplan-Meier curves of five-year overall survival rate of patients with right and left-sided colon cancer stage I&II.”
The clinical utility of circulating tumor DNA in colorectal cancer: A narrative review
Lakshmi, V., Rakesh, M., Narmadha, M. P., Sudhindran, S., Balakrishnan, D., & Koyakutty, M. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_225_23 · Cited by 2
Moreno‐Viedma, V., Adachi-Fernandez, E., Krauß, D., Mohr, T. T., Blauensteiner, B., Buresch, J., Mireva, L., Kokkinogenis, E., Filipits, M., Holcmann, M., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01828-0 · Cited by 1
Challenges and opportunities in the treatment of metastatic colorectal cancer
de España, R. A. N. D. M., & Díaz-Rubio, E. (2018) · ANALES RANM · doi:10.32440/ar.2018.135.02.rev08 · Cited by 1
Biopokazatelji malignih bolesti crijeva
Brajković, M. (2018) · Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)
Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review
Palathingal, J. T., Sunny, B. C., & Vijayan, V. (2020) · Clinical Cancer Drugs · doi:10.2174/2212697x07999201029200025
Nadira, R. Q. (2026) · Research Publications (Maastricht University) · doi:10.26481/dis.20261104nr
Karabağ, S., Öznur, M., Bilen, Y. G., & Avcı, O. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.125213
Metadata
- Authors
- Atreya, C. E., Yaeger, R., & Chu, E.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2017-05
- Volume
- 37
- Issue
- 37
- Pages
- 246-256
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4244654711
- Cited by
- 35
- References
- 66
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 8 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 1
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K08CA175153)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, systemic therapy, first-line therapy, targeted therapy, predictive biomarkers, prognostic factors, next-generation sequencing, exome sequencing, circulating tumor DNA, personalized medicine, chemotherapy
- MeSH terms
- Humans, Neoplastic Cells, Circulating, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Precision Medicine, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.